EMD-41617

Single-particle
3.12 Å
EMD-41617 Deposition: 15/08/2023
Map released: 15/11/2023
Last modified: 21/02/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-41617

CryoEM structure of PI3Kalpha

EMD-41617

Single-particle
3.12 Å
EMD-41617 Deposition: 15/08/2023
Map released: 15/11/2023
Last modified: 21/02/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Homo sapiens
Sample: PI3Kalpha
Fitted models: 8tu6

Deposition Authors: Valverde R , Shi H, Holliday M , Sun M
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3K alpha Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
PUBMED: 37916956
DOI: doi:10.1158/2159-8290.CD-23-0944
ISSN: 2159-8290